1029P Addition of dendritic cell vaccines to neoadjuvant chemotherapy in HER2 negative breast cancer patients

Urrizola, Amaia; Solans, Belén P; Bayona, R. Sánchez; Mejías, Luis D.; Vilalta, A.; Cruz, Susana De La; Olartecoechea, Begoña; Rodríguez-Spiteri, N.; Hato, Laura; Cerio, Ascension Lopez Diaz de; Inogés, Susana; Eslava, Marta Santisteban

doi:10.1016/j.annonc.2020.08.1149

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary outcome measure was pCR, which was significantly higher in VG (26.3%) compared to a historic cohort of 44 patients treated with NAC alone as the CG (9.09%) after 7.5 years of follow-up. Additionally, no grade ≥ 3 vaccine-related AEs were observed [ 53 ]. In a further record, pCR rate was reported to be 17% vs. 67% in CG and VG of the TNBC sub-population, and significantly increased CD8-TIL levels were also observed in TNBC patients not reaching pCR [ 54 ].…”

Section: Resultsmentioning

confidence: 99%

Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the poorest outcomes, and is associated with a high risk of relapse and metastasis. The treatment choices for this malignancy have been confined to conventional chemotherapeutic agents, due to a lack of expression of the canonical molecular targets. Immunotherapy has been recently changing the treatment paradigm for many types of tumors, and the approach of evoking active immune responses in the milieu of breast tumors through cancer vaccines has been introduced as one of the most novel immunotherapeutic approaches. Accordingly, a number of vaccines for the treatment or prevention of recurrence have been developed and are currently being studied in TNBC patients, while none have yet received any approvals. To elucidate the efficacy and safety of these vaccines, we performed a systematic review of the available literature on the topic. After searching the PubMed, Scopus, Web of Science, Embase, Cochrane CENTRAL, and Google Scholar databases, a total of 5701 results were obtained, from which 42 clinical studies were eventually included based on the predefined criteria. The overall quality of the included studies was acceptable. However, due to a lack of reporting outcomes of survival or progression in some studies (which were presented as conference abstracts) as well as the heterogeneity of the reported outcomes and study designs, we were not able to carry out a meta-analysis. A total of 32 different vaccines have so far been evaluated in TNBC patients, with the majority belonging to the peptide-based vaccine type. The other vaccines were in the cell or nucleic acid (RNA/DNA)-based categories. Most vaccines proved to be safe with low-grade, local adverse events and could efficiently evoke cellular immune responses; however, most trials were not able to demonstrate significant improvements in clinical indices of efficacy. This is in part due to the limited number of randomized studies, as well as the limited TNBC population of each trial. However, due to the encouraging results of the currently published trials, we anticipate that this strategy could show its potential through larger, phase III randomized studies in the near future.

show abstract

Section: Resultsmentioning

confidence: 99%